The Asia Pacific Organ Preservation Market size was valued at USD 44.56 million in 2021 and is expected to grow at a CAGR of 6.5% and worth USD 61.05 million by 2026.
Y-O-Y growth in the number of organ failures and incidence of chronic diseases among the Asia-Pacific countries are majorly promoting the organ preservation market in this region. Technological advancements play a significant role in upgrading the healthcare system and are estimated to boost the APAC organ preservation market in this scenario. The demand for novel and innovative treatment options has increased, which is expected to favor market growth during the forecast period.
Y-O-Y growth in the number of organ transplantations happening across the APAC region increased organ donations, and growing demand for diagnostic services are further expected to augment the organ preservation market in APAC. The growing incidence of multiple organ failures in the aged population and rising medical tourism in the APAC region are estimated to favor the APAC organ preservation market during the forecast period.
An increasing number of initiatives by the APAC countries to create awareness among the people to organ donations is expected to boost the growth rate of the APAC organ preservation market. Sufficient availability of cold storage among the end-users, insurance coverage through Medicare, and other private insurance companies such as India and Japan for the transplantation processes are adding fuel to the growth rate of the market. Favorable reimbursement policies and growing funds and investments to launch novel storage devices are likely to fuel the APAC organ preservation market during the forecast period.
However, high costs associated with organ transplantations are majorly restraining the APAC organ preservation market growth. The presence of stem cell therapies, lack of communication, and organizational support are significant challenges to the APAC organ preservation market.
This research report on the Asia Pacific Organ Preservation Market has been segmented and sub-segmented into the following categories:
By Preservation Solution:
By Transportation Technique:
By Organ Type:
Geographically, the APAC organ preservation market is expected to be dominated by China and India. The Chinese organ preservation market is estimated to be the fastest-growing APAC region due to the increased awareness regarding organ donations. The increased awareness over the health and availability of new treatment procedures and the growing population further boosts the Chinese organ preservation market. Advancements in organ transplantations and augmenting public education help increase the number of organ donations in China.
The Indian organ preservation market is driven by the swift developments in healthcare infrastructure and growing medical tourism. On 20 September 2018, Apollo Hospitals, Chennai, successfully implemented liver transplantation for the first time and was a huge success. The organ transplantation used the OrganOx Metra device, a new organ preservation device and maintains the liver at average temperature and aids in developing tissue fertility, decreasing the rejection rate of organs appropriate for organ donations and transplantations.
The Japanese organ preservation market is expected to register a healthy growth rate during the forecast period. The enthusiasm in donating organs resulted in advancements in donating organs against religious issues, accelerate Japan's organ preservation market growth.
The organ preservation market in countries such as Australia, New Zealand, South Korea, Indonesia, and Thailand is expected to grow at a moderate CAGR during the forecast period.
KEY MARKET PLAYERS:
Some notable companies operating in the Asia Pacific Organ Preservation Market profiled in the report are Essential Pharmaceuticals, Dr. Franz Kohler Chemie GmbH, Organ Recovery Systems, Xvivo Perfusion AB, and Waters Medical Systems LLC.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Static Cold Storage (SCS) Technique
5.1.3 Hypothermic Machine Perfusion
5.1.4 Normothermic Machine Perfusion
5.1.5 Y-o-Y Growth Analysis, By Technique
5.1.6 Market Attractiveness Analysis, By Technique
5.1.7 Market Share Analysis, By Technique
5.2 Preservation Technique
5.2.2 University of Wisconsin Solution (UW Solution)
5.2.3 Custodiol HTK
5.2.5 Other Preservation Solutions
5.2.6 Y-o-Y Growth Analysis, By Preservation Technique
5.2.7 Market Attractiveness Analysis, By Preservation Technique
5.2.8 Market Share Analysis, By Preservation Technique
5.3 Organ Type
5.3.6 Other Organs (Pancreas, Intestine)
5.3.7 Y-o-Y Growth Analysis, By Organ Type
5.3.8 Market Attractiveness Analysis, By Organ Type
5.3.9 Market Share Analysis, By Organ Type
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Technique
22.214.171.124 By Preservation Technique
126.96.36.199 By Organ Type
6.1.4 Market Attractiveness Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Technique
220.127.116.11 By Preservation Technique
18.104.22.168 By Organ Type
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Technique
188.8.131.52 By Preservation Technique
184.108.40.206 By Organ Type
6.5 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Waters Medical Systems LLC [Institut Georges Lopez (IGL]
8.1.2 Technique Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bridge to Life Limited
8.3 Organox Limited
8.4 Transmedics, Inc.
8.5 Xvivo Perfusion AB
8.6 Preservation Solutions, Inc.
8.7 Lifeline Scientific, Inc. (Organ Recovery Systems, Inc.)
8.8 Essential Pharmaceuticals, LLC
8.9 Dr. Franz Kohler Chemie GmbH
8.10 21st Century Medicine Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures